Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FORESIGHT: Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy: a Randomised Controlled Trial Against Aprepitant in Triple Therapy

NCT04075955 is registered in ClinicalTrials.gov with CR-CSSS Champlain-Charles-Le Moyne as lead sponsor.

NCT NCT04075955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04075955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FORESIGHT: Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy: a Randomised Controlled Trial Against Aprepitant in Triple Therapy
Lead sponsor
CR-CSSS Champlain-Charles-Le Moyne
Phase
Phase 3
Overall status
Completed
Start date
April 29, 2019
Completion date
December 31, 2019
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced nausea and vomiting